Cantex Pharmaceuticals
Latest round
- Series D
Last raised
- Nov 2014
Total raised
- $25M
Investors
- 5
About Cantex Pharmaceuticals
Cantex Pharmaceuticals, Inc.Cantex Pharmaceuticals, Inc. is dedicated to the development of innovative oral treatments for cancer and inflammatory conditions.252 mn.Cantex Pharmaceuticals, Inc. specializes in the development of innovative, orally administered treatments aimed at addressing various cancer types and inflammatory lung diseases. Their core product, azeliragon, is an oral small molecule currently undergoing clinical trials for its efficacy in treating brain metastasis from breast cancer, pancreatic cancer, and nervous system cancers. This medication is designed to be safe and well-tolerated, providing a once-daily dosing option for patients, thereby enhancing compliance and convenience. Cantex's therapeutic focus also extends to inflammatory lung diseases, including severe pneumonia, asthma, and chronic obstructive pulmonary disease (COPD).Cantex Pharmaceuticals operates within a clinical stage framework, primarily focused on the research and development of its flagship product, azeliragon. Revenue generation will be driven by partnerships with pharmaceutical distributors and healthcare providers, potentially involving B2B transactions where azeliragon is supplied to hospitals and clinics specializing in oncology and respiratory diseases. Transaction structures may include licensing agreements or partnerships for co-development, which will facilitate broader access to their therapies upon successful completion of clinical trials and subsequent approvals.Cantex Pharmaceuticals plans to expand its product portfolio, focusing on new indications for azeliragon, with specific timelines for clinical trial completion yet to be announced. The company is also looking to expand its market reach into new geographic regions, targeting oncology and respiratory care providers globally.
Who invested in Cantex Pharmaceuticals
5 investors across 3 rounds
See all investors in Cantex Pharmaceuticals
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Cantex Pharmaceuticals
Who invested in Cantex Pharmaceuticals?
Cantex Pharmaceuticals has 5 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Cantex Pharmaceuticals raised?
Cantex Pharmaceuticals has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Cantex Pharmaceuticals last raise money?
Cantex Pharmaceuticals's most recent round on record is a Series D, in Nov 2014.
What does Cantex Pharmaceuticals do?
Cantex Pharmaceuticals is a pharmaceuticals company.
Where is Cantex Pharmaceuticals headquartered?
Cantex Pharmaceuticals is headquartered in Weston, US.
Which VCs invest in companies like Cantex Pharmaceuticals?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back pharmaceuticals companies at Cantex Pharmaceuticals's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series D
Raising like Cantex Pharmaceuticals? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.